it is not necessary to consider other points of invalidity that will arise on the hearing.
at the very least, the statement in the canadian specification "the invention also concerns each of the enantiomers and their mixture", the formula for the compound example 1, and the statements in claim 1 "as well as the 2 enantiomers or their mixture of these compounds of formula (i)" and "and, if desired, its enantiomers are separated and/or it is salified by mineral or organic acid action", give substance to the claim of invalidity by genrx.
the most influential consideration of the issue in relation to patents was that by gummow j in martin engineering co v trison holdings pty ltd (1988) 81 alr 543.